ProfileGDS5678 / 1430526_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 80% 80% 79% 82% 83% 82% 80% 80% 80% 82% 80% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7059981
GSM967853U87-EV human glioblastoma xenograft - Control 25.6706980
GSM967854U87-EV human glioblastoma xenograft - Control 35.6705780
GSM967855U87-EV human glioblastoma xenograft - Control 45.6493679
GSM967856U87-EV human glioblastoma xenograft - Control 55.9193282
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8335883
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7821782
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6756480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6436780
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6294380
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8950582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6451980
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6615780
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6592980